A precision strike against liver fibrosis: Targeting vascular ROCK2
A landmark study published in *Cell* reveals a novel therapeutic strategy for liver fibrosis by targeting a specific cell signaling pathway. Researchers identified that ROCK2, a kinase, is selectively upregulated in endothelial and perivascular cells during liver disease, driving fibrogenic vascular dysfunction. The research demonstrates that TDI01, a selective ROCK2 inhibitor, effectively treats fibrosis in preclinical models of metabolic dysfunction-associated steatohepatitis (MASH) and shows promising anti-fibrotic potency in clinical trials involving human patients. This work highlights the critical role of angiocrine signaling—signals from blood vessel cells—in disease progression and opens a new avenue for precision medicine in chronic liver conditions.
Study Significance: This finding shifts the therapeutic focus in liver fibrosis from broad anti-inflammatory approaches to precise modulation of cell signaling within the vascular niche. For researchers and clinicians, it validates ROCK2 as a high-value target and underscores the importance of cell-type-specific pathway analysis in complex diseases. The successful translation from preclinical models to human trials provides a robust framework for developing similar targeted therapies against oncogenes and tumor suppressors in the tumor microenvironment.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
